Dr. Pamela Nathan DHM L.Ac. has been delivering health to your front door since 1998. Happy patients in over 78 countries. Want an Appointment? Book Now

Free Shipping Over $69**

Shopping Cart

Your cart is currently empty.

VSL#3 Induces Remission for Ulcerative Colitis

VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

An article published in the National Library of Medicine National Institute of Health last year showed that the results of a human clinical for the treatment of patients with mild to moderate Ulcerative Colitis. Patients were given VSL#3 for 6 weeks. At the end of the 6 week period those patients had a remission rate of 77% with no adverse side effects.

VSL#3 Probiotics

VSL#3 Probiotics

How Does VSL#3 Probiotic Work?

Many probiotic formulas contain beneficial bacteria, but due to differences in types of bacteria and preparation of the products, these bacteria die off from varying conditions throughout the GI tract and never make it to the place they need to be. Studies shows that probiotics from VSL#3 do make it to the colon, which is the area they need to reach to be effective.

A study conducted with VSL#3 confirms that maximum bacterial colonization of the gut occurs within 20 days.

Prebiotic Fiber with PHGG

Prebiotic Fiber

It’s not really one of those things where you can just take it for a few weeks and think you are good to go. You are essentially adding new bacteria to your gut to recolonize it.

We find most of our clients have the greatest success when pairing VSL#3 with a prebiotic fiber containing partially hydrolyzed guar gum to help feed the probiotics so they grow and multiply in numbers.

Another study conducted on children with Ulcerative Colitis also showed promising results. One 4 week study, conducted on children with UC, found that after the 4 week period where treatment included steroid therapy along with either VSL#3 or placebo, 92.8% in the VSL#3 group achieved remission, compared with only 36.4% in the placebo group.

To maintain the remission, the researchers gave the children 5-ASA along with either VSL#3 or placebo. They then monitored the children over the next 12 months, and found that 73.3% of those who had 5-ASA and placebo experienced a relapse, compared with only 21.4% of those who were taking 5-ASA and VSL#3. This study also reported no adverse side effects from VSL#3.

For more studies on VSL#3 helping with management of Ulcerative Colitis click here. 

VSL#3 Probiotics Help Colitis Remission – Research by Fedorak et al Jul 2005

Am J Gastroenterol. 2005 Jul;100(7):1539-46.

VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Source

Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.

Abstract

BACKGROUND AND AIMS:

Intestinal bacteria have been implicated in the initiation and perpetuation of IBD; in contrast, “probiotic bacteria” have properties possibly effective in treating and preventing relapse of IBD. We evaluated the safety and efficacy of VSL#3 and the components, and the composition of the biopsy-associated microbiota in patients with active mild to moderate ulcerative colitis (UC).

METHODS:

Thirty-four ambulatory patients with active UC received open label VSL#3, 3,600 billion bacteria daily in two divided doses for 6 wk. The presence of biopsy-associated bacteria was detected using a nucleic acid-based method and the presence of VSL#3 species confirmed by DNA sequencing of 16S rRNA.

RESULTS:

Thirty-two patients completed 6 wk of VSL#3 treatment and 2 patients did not have the final endoscopic assessment. Intent to treat analysis demonstrated remission (UCDAI < or = 2) in 53% (n = 18); response (decrease in UCDAI > or = 3, but final score > or =3) in 24% (n = 8); no response in 9% (n = 3); worsening in 9% (n = 3); and failure to complete the final sigmoidoscopy assessment in 5% (n = 2). There were no biochemical or clinical adverse events related to VSL#3. Two of the components of VSL#3 were detected by PCR/DGGE in biopsies collected from 3 patients in remission.

CONCLUSION:

Treatment of patients with mild to moderate Ulcerative Colitis, not responding to conventional therapy, with VSL#3 resulted in a combined induction of remission/response rate of 77% with no adverse events. At least some of the bacterial species incorporated in the probiotic product reached the target site in amounts that could be detected.

PMID:

 15984978[PubMed – indexed for MEDLINE]

Copyright © 2017 Ecology Health Center / Crohns.net - HealthyLifeUSA.